PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
5.68%
Net income growth under 50% of VET's 434.35%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
-15.45%
Negative yoy D&A while VET is 22.20%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
6.23%
Lower deferred tax growth vs. VET's 85.26%, implying fewer future tax liabilities. David Dodd would confirm there’s no short-term tax shock instead.
366.67%
SBC growth while VET is negative at -6.06%. John Neff would see competitor possibly controlling share issuance more tightly.
1933.33%
Well above VET's 106.72% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1933.33%
Growth well above VET's 106.72%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-38.95%
Both negative yoy, with VET at -116.05%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-38.17%
Negative yoy CFO while VET is 494.64%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-0.95%
Negative yoy CapEx while VET is 48.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
-83.29%
Negative yoy acquisition while VET stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
-116.44%
Negative yoy purchasing while VET stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
442.34%
Liquidation growth of 442.34% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in monetizing portfolio items that must be justified by market valuations.
0.99%
We have some outflow growth while VET is negative at -423.68%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
-354.10%
We reduce yoy invests while VET stands at 19.88%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
-1508.54%
We cut debt repayment yoy while VET is 78.73%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-100.00%
Negative yoy issuance while VET is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.